BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,040
Employees3,040
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,040
Employees3,040

BMRN Key Statistics

Market cap
10.49B
Market cap10.49B
Price-Earnings ratio
20.73
Price-Earnings ratio20.73
Dividend yield
Dividend yield
Average volume
2.48M
Average volume2.48M
High today
$55.85
High today$55.85
Low today
$54.16
Low today$54.16
Open price
$55.00
Open price$55.00
Volume
2.23M
Volume2.23M
52 Week high
$73.51
52 Week high$73.51
52 Week low
$50.76
52 Week low$50.76

Stock Snapshot

The current BioMarin(BMRN) stock price is $54.22, with a market capitalization of 10.49B. The stock trades at a price-to-earnings (P/E) ratio of 20.73.

As of 2025-11-13, BioMarin(BMRN) stock has fluctuated between $54.16 and $55.85. The current price stands at $54.22, placing the stock +0.1% above today's low and -2.9% off the high.

The BioMarin(BMRN)'s current trading volume is 2.23M, compared to an average daily volume of 2.48M.

During the past year, BioMarin(BMRN) stock moved between $50.76 at its lowest and $73.51 at its peak.

During the past year, BioMarin(BMRN) stock moved between $50.76 at its lowest and $73.51 at its peak.

BMRN News

Simply Wall St 2d
Should FDA Priority Review for Expanded PALYNZIQ Use Prompt Action From BioMarin Investors?

BioMarin Pharmaceutical announced that the FDA has accepted for Priority Review its supplemental Biologics License Application to expand PALYNZIQ® treatment for...

Should FDA Priority Review for Expanded PALYNZIQ Use Prompt Action From BioMarin Investors?
Nasdaq 3d
BMRN February 2026 Options Begin Trading

Investors in BioMarin Pharmaceutical Inc (Symbol: BMRN) saw new options begin trading today, for the February 2026 expiration. One of the key data points that g...

BMRN February 2026 Options Begin Trading
Simply Wall St 6d
BioMarin Pharmaceutical: Fresh Valuation Insights Following Raised Guidance and Product Momentum

BioMarin Pharmaceutical (BMRN) recently delivered its third quarter results, demonstrating ongoing revenue growth led by strong uptake of VOXZOGO and PALYNZIQ....

BioMarin Pharmaceutical: Fresh Valuation Insights Following Raised Guidance and Product Momentum

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
20.7%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.